Top Markets
Coin of the day
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc.

PVCT
Classificação em ações #28855
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm... Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm dedicated to pioneering immunotherapy treatments. These therapies are grounded in its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy. This treatment is being explored for a range of adult solid tumor malignancies, encompassing melanoma and various gastrointestinal cancers (such as hepatocellular carcinoma, metastatic colorectal cancer to the liver, metastatic neuroendocrine tumors to the liver, and metastatic uveal melanoma to the liver). It also targets pediatric solid tumors, including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. Additionally, Provectus is advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) to combat a broad spectrum of conditions. These include adult solid tumors (such as head and neck, breast, testicular, and colorectal cancers), pediatric blood cancers like leukemia, acute respiratory syndromes such as coronavirus, infections caused by multi-drug resistant bacteria (specifically Gram-negative bacteria), and certain ocular conditions, notably infectious keratitis. Furthermore, the company is progressing PH-10, an investigational immuno-dermatology agent designed to address inflammatory skin conditions like psoriasis and atopic dermatitis. Originally established in 2002, the company was initially named Provectus Pharmaceuticals, Inc., before rebranding as Provectus Biopharmaceuticals, Inc. in December 2013. Its operations are headquartered in Knoxville, Tennessee.
Preço da ação
$0.0578
Valor de mercado
$24.29M
Variação (1 dia)
1.40%
Variação (1 ano)
-27.93%
País
US
Negociar Provectus Biopharmaceuticals, Inc. (PVCT)

Categoria

Preço PVCT com a capitalização de mercado de B
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.
PVCT
$0.0578
Capitalização de mercado de Provectus Biopharmaceuticals, Inc.(PVCT)
Valor de mercado: $24.29M
Em August 2026, Provectus Biopharmaceuticals, Inc. tem uma capitalização de mercado de $24.29M. Isso faz com que Provectus Biopharmaceuticals, Inc. seja a 28855th empresa mais valiosa do mundo em termos de capitalização de mercado, de acordo com os nossos dados. A capitalização de mercado, também chamada de market cap, é o valor total de mercado das ações em circulação de uma empresa de capital aberto e é amplamente utilizada para medir o valor de uma empresa.
Histórico de capitalização de mercado de Provectus Biopharmaceuticals, Inc. de 1997 a 2026
PVCT comparado com o topo de 5 mais populares stocks
Preço para PVCT Ativo B Capitalização de mercado de B Resultados
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.
$12,634.37 $24.29M
$5.310T +21,858,664.40%
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.
$11,033.69 $24.29M
$4.637T +19,089,333.28%
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.
$9,840.57 $24.29M
$4.136T +17,025,110.24%
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.
$8,542.00 $24.29M
$3.590T +14,778,446.51%
Provectus Biopharmaceuticals, Inc. Provectus Biopharmaceuticals, Inc.
$6,761.97 $24.29M
$2.842T +11,698,803.24%